← Back to Home

FDA Confirms Evidence of Insertional Oncogenesis in Two Zolgensma Cases, Reviews Labeling and Long-Term Follow-Up

Tumor reports now have more specific molecular evidence: in two cases, the treatment vector was found integrated near or within the GLI1 oncogene. The FDA is assessing whether safety labeling and follow-up studies are adequate, and is extending its risk assessment to Itvisma, which uses the same vector.

By SURL BioNews

For families receiving gene therapy for spinal muscular atrophy (SMA), clearer answers are needed about long-term safety as well as efficacy. On November 6, the U.S. Food and Drug Administration (FDA) announced that, among reports of malignant tumors following Zolgensma treatment, two cases now have confirmed evidence of cancer caused by insertion of the treatment vector into the genome. The agency is reviewing whether drug labeling and long-term follow-up studies adequately address this risk.

The key development in this update is the molecular analysis of tumor tissue. The FDA said three tumor cases involved the GLI1 oncogene. In two cases, DNA from Zolgensma’s adeno-associated virus (AAV) vector was found integrated into the patients’ genomes, with the promoter in the therapeutic construct located upstream of or within GLI1. Overexpression or abnormal activation of GLI1 may contribute to cancer; the mechanism behind its overexpression in the third case remains unclear.

The FDA has also extended its tumor risk assessment to Itvisma. The two products use the same vector and gene construct, but differ in their routes of administration and indicated ages: Zolgensma is administered by intravenous infusion to children with SMA younger than two years, while Itvisma is administered by intrathecal injection and is indicated for patients aged two years and older. As of the announcement, no tumor cases had been reported with Itvisma; the basis for this assessment is the products’ shared design.

The overall context of the nine tumor reports still requires careful interpretation. A statement from an expert team in England published by Muscular Dystrophy UK said that pathological testing had been completed in three of the nine cases: two were considered related to treatment, while one appeared unrelated. A Novartis statement republished by the organization said that more than 6,000 people worldwide had received treatment, and that both patients with evidence of vector DNA integration had received treatment and remained under follow-up. These reports and the cumulative number of people treated are not sufficient to directly calculate the incidence of cancer caused by the therapy.

Following the public disclosure, families and medical teams still have many questions. STAT reported on November 5 that seven of the nine reports had not previously been disclosed, and that Novartis had communicated the information to neurologists earlier that week. The U.S. Muscular Dystrophy Association (MDA) said the same day that it was reviewing the data with clinical and research experts and seeking information from the company. Information gaps remain regarding when the events occurred, tumor characteristics, and what monitoring may be needed in the future.

Follow-up arrangements are also a focus of the regulatory review. In its November 6 statement, the expert team in England did not recommend additional scans or tests, or changes to routine care, based on the information available at the time. The FDA, meanwhile, said that patients and trial participants treated with the relevant products should be monitored for tumor formation, and that it was assessing whether current labeling and long-term studies were adequate. The two statements differ in how they describe monitoring, and they do not currently provide a basis for proposing a universal set of additional tests.

The U.S. labeling for Zolgensma and Itvisma already listed a theoretical risk of tumor formation from vector DNA integration. The emergence of evidence of product-related insertional oncogenesis now gives that warning a basis in actual cases. The FDA continues to consider the overall benefits of both products to outweigh their potential risks for their approved uses, while assessing whether to take regulatory action. The central question ahead is how to translate the new evidence into more complete risk communication and long-term follow-up.

References

  1. FDA
  2. Muscular Dystrophy UK
  3. STAT
  4. Muscular Dystrophy Association